Medical Surveillance and Communications, Medical Affairs, at Norwich Eaton Pharmaceuticals, Inc. is responsible for monitoring, evaluating, classifying and communicating all facets of possible adverse reactions to company products. Worldwide literature and data on investigational drugs and marketed ethical products are entered into a comprehensive computer database for later retrieval as required. Adverse reaction trends are identified and disseminated as appropriate. Medical Surveillance and Communications also performs drug information services commensurate with the needs of the company, interfacing with various members of Medical Affairs and other appropriate company personnel.
WorthenDB: Industry's role in drug information. Drug Inf J1977;11:238–241.
2.
National Adverse Drug Reaction Directory (“COSTART”), US Department of Health, Education, and Welfare. Public Health Service. Food and Drug Administration.
3.
KarchFELasagnaL: Adverse drug reactions. A critical reviewJAMA1975;234:1236–1241.
4.
KarchFESmithCLKerznerBMazzulloJMWeintraubMLasagnaL: Commentary. Adverse drug reactions—- A matter of opinion. Clin Pharmacol Ther1976;19:489–492.
5.
KarchFELasagnaL: Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther1977;21:247–254.
6.
LeeBTurnerWM: Food and Drug Administration's adverse drug reaction monitoring program. Am J Hosp Pharm1978;35:929–932.
7.
RowlesBWorthenDB: Clinical drug information: A case of misinformation. Letter to the editor. N Engl J Med1982;306:113–114.
8.
MeadowsRJ: Drug information: The pharmaceutical manufacturer's viewpoint and involvement. Drug Inf J1977;11:221–224.
